SEO URLwww.firestrike.ai/deals/merus-genmab-acquisition-2026
acquisitionAnnounced · Jan 28, 2026BiotechnologySource · FactualArticle · Factual
Genmab acquires Merus
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$8B
Target
Merus
Nasdaq: MRUS
Acquirer
Genmab
Full Acquisition
Status
Pending
Genmab agreed to acquire Merus. Reported deal value: $8B. Status: Pending. Sector: Biotechnology. Target headquarters context: Location not specified.
This page summarizes publicly available information about the transaction as of 2026-01-28. Figures and status may change as filings and press coverage update.
Photo: Novo Holdings / Pr When Genmab acquired Dutch company Merus for USD 8bn in November last year, it was not only the Danish pharmaceutical company that stood to gain, acquiring a promising cancer drug in the process
Deal timeline
Announced
Jan 28, 2026 · medwatch.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biotechnology with a reported deal value of $8B. Figures and status may change as sources update.
Sources: medwatch.com · Primary article · FireStrike proprietary index